Jesse D Roberts Jr., M.D. M.S.


Principal Investigator
Cardiovascular Research Center, Massachusetts General Hospital
Research Scientist
Medicine, Massachusetts General Hospital
Research Staff
Pediatrics, Massachusetts General Hospital
Associate Professor of Anaesthesia
Harvard Medical School
Associate Anesthetist
Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital
M.S. (Biochemistry) University of Rochester 1982
Anesthesiology MGH / Harvard Medical School 1990
Pediatric Anesthesiology Boston Children's Hospital 1990
Pediatrics UCSD 1985
MD University of Rochester School of Medicine and Dentistry 1982
Neonatology Brown University 1987
bronchopulmonary dysplasia; cyclic gmp; cyclic gmp-dependent protein kinases; guanylate cyclase; muscle smooth; nitric oxide; nuclear localization signals; persistent fetal circulation syndrome; pulmonary alveoli; pulmonary artery; pulmonary vascular diseases; transforming growth factor beta; vascular The major goal of my laboratory is to explore the fundamental mechanisms of newborn lung injury so that we can develop novel therapies that prevent or treat important pediatric pulmonary diseases. Lung injury often causes abnormal pulmonary development and function in newborns and infants. For example, in infants with some forms of congenital heart disease, lung injury can cause an abnormal increase in the smooth muscle cells in the blood vessels of the lung periphery and, in part through this mechanism, pulmonary hypertension and heart failure. In premature infants, lung injury associated with life-sustaining ventilation of the lungs with oxygen often decreases pulmonary microvascluar and alveolar development and bronchopulmonary dysplasia, a chronic lung disease. Our laboratory has investigated the mechanisms by which nitric oxide (NO) and cGMP regulates pulmonary development and function in the newborn. We have discovered mechanisms by which NO and cGMP signaling are disrupted during newborn lung injury and developed inhaled NO as a novel, life-saving therapy to prevent or treat newborn lung diseases. We have also detailed how NO and cGMP regulate the function of cells within the lung. In particular, we identified new mechanisms that regulate the intracellular compartmentation of cGMP-signaling enzymes. We are very gratified that our work has lead to the development and world-wide use of therapies that treat lung disease in critically ill newborns and pediatric patients.
Research lab website Publications Clinical Profile
roberts@cvrc.mgh.harvard.edu
6177243104
Cardiovascular Research Center
CNY-Building #149
149 13th Street
Charlestown, MA 02129